With the Food and Drug Administration Amendments Act (FDAAA) of 2007 barely in the rear view mirror and the Prescription Drug User Fee Act V reauthorization rapidly approaching, drug safety, risk evaluation and mitigation strategy (REMS), and pharmacovigilance in the United States are about to undergo significant changes.
Meanwhile, the United Kingdom is forging ahead with its most significant pharmacovigilance legislation since 1995, with serious implications for applicants and holders of European Union marketing authorizations.
What will these changes mean for the pharma industry worldwide?
Please join the Center for Medicine in the Public Interest (www.cmpi.org) and FDA News for the 4th Annual Risk Management and Drug Safety Summit: Building an Effective Global Risk Management and Drug Safety Program, scheduled for Nov. 1–2, 2011, in Washington D.C.
Keynote speakers:
• Peter Pitts, co-founder, president, Center for Medicine in the Public Interest (chair)
• Edward Fotsch, M.D., CEO, PDR Network LLC (chair)
• John Lechleiter, Ph.D., CEO, Eli Lilly & Co.
• Janet Woodcock, M.D., director, Center for Drug Evaluation and Research (CDER), FDA
• Sir Alasdair Breckenridge, chairman, Medicines & Healthcare Products Regulatory Agency, UK
• Ravi Deshpande, vice president, McKesson Specialty
• John Jenkins, M.D., director, Office of New Drugs, CDER, FDA (invited)
• Ankur Makadia, PharmD, risk management plan leader, Global Clinical Safety & Pharmacovigilance, UCB
• Jane Axelrad, associate director for policy, CDER, FDA (invited)
• Deborah Autor, deputy commissioner, Globalization & Regulatory Operations, OC, FDA
• Josephine Torrente, director, Hyman, Phelps & McNamara (invited)
• Vaishali Patadia, Ph.D., director, head, Pharmacoepidemiology, Astellas Pharma (invited)
• Timothy Franson, M.D., senior vice president, health and life sciences sector, B&D Consulting; president, U.S. Pharmacopeia Board of Trustee; former vice president, global regulatory affairs, Eli Lilly & Co. research laboratories
Click here to see the full agenda.
Stratagems on REMS
Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.
